$43.62
0.160.37%
At close: Sep 11, 5:00 PM EST

Rapport Therapeutics (RAPP) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.97 | $-0.68 | $-0.66 | $-0.75 |
| Actual | $-1.19 | $-0.42 | $-0.72 | $-0.71 |
| Surprise | -22.7% | +38.2% | -9.09% | +5.33% |
| Revenue | ||||
| Estimate | $4.0M | $8.8M | — | — |
| Actual | $0 | $20.0M | $0 | — |
| Surprise | -100.0% | +127.3% | — | — |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-1.23 | $-1.23 | $-1.27 | $-1.29 |
| Revenue | ||||
| Consensus | — | — | — | — |
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q2 | Aug 5, 2026 | $-1.19 | $-0.97 | -22.7 % |
| Q1 | May 7, 2026 | $-0.42 | $-0.68 | 38.2 % |
| Q4 | Mar 10, 2026 | $-0.72 | $-0.66 | -9.09 % |
| Q3 | Nov 6, 2025 | $-0.71 | $-0.75 | 5.33 % |
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q2 | Aug 5, 2026 | $0 | $4.00M | -100.0 % |
| Q1 | May 7, 2026 | $20.00M | $8.80M | 127.3 % |